A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

NCT05952869 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

303

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia
Familial Hypercholesterolemia

Interventions

DRUG: Enlicitide Decanoate
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC